Rio Tinto (NYSE:RIO) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.

Risk & Volatility

Rio Tinto has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500.

Insider & Institutional Ownership

7.1% of Rio Tinto shares are held by institutional investors. Comparatively, 4.8% of Opiant Pharmaceuticals shares are held by institutional investors. 37.9% of Opiant Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Rio Tinto and Opiant Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rio Tinto 2 9 7 0 2.28
Opiant Pharmaceuticals 0 0 1 0 3.00

Rio Tinto currently has a consensus price target of $55.67, indicating a potential upside of 7.87%. Opiant Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 84.76%. Given Opiant Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Opiant Pharmaceuticals is more favorable than Rio Tinto.

Dividends

Rio Tinto pays an annual dividend of $2.54 per share and has a dividend yield of 4.9%. Opiant Pharmaceuticals does not pay a dividend. Rio Tinto pays out 53.0% of its earnings in the form of a dividend.

Valuation & Earnings

This table compares Rio Tinto and Opiant Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rio Tinto $40.03 billion 1.70 $8.76 billion $4.79 10.78
Opiant Pharmaceuticals $18.45 million 2.65 $6.58 million $2.94 5.89

Rio Tinto has higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a lower price-to-earnings ratio than Rio Tinto, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rio Tinto and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rio Tinto N/A N/A N/A
Opiant Pharmaceuticals -449.52% -471.43% -190.80%

Summary

Rio Tinto beats Opiant Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Rio Tinto Company Profile

Rio Tinto plc, a mining and metals company, explores for, develops, produces, and processes minerals and metals worldwide. It finds, mines, and processes mineral resources, including aluminum, copper, diamonds, gold, industrial minerals (borates, titanium dioxide, and salt), iron ore, thermal and metallurgical coal, and uranium, as well as sulphuric acid, rhenium, lead carbonate, and selenium. The company was founded in 1873 and is headquartered in London, the United Kingdom. Rio Tinto plc operates as a subsidiary of Rio Tinto Group.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

Receive News & Ratings for Rio Tinto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rio Tinto and related companies with MarketBeat.com's FREE daily email newsletter.